ArticleJournal for immunotherapy of cancer2019
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Matthew J Reilley et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
53 papers cite it
this paperpooled ittrialcites it